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We report the total chemical synthesis of human C3a by one-
pot native chemical ligation of three unprotected peptide 
segments followed by efficient in-vitro folding, which yielded 
the target molecule in high yield and excellent purity. The 10 
synthetic material was fully active and facilitated 
determination of the C3a crystal structure at 2.1Å resolution.  
The anaphylatoxins C3a and C5a are key mediators of the 
complement system, which represents the first line of 
immunological defense for the recognition and elimination of 15 
microbes and pathogens.1 They selectively bind to their 
respective G protein-coupled receptors (C3aR and C5aR) 
triggering a variety of pro-inflammatory processes and have 
recently been linked to a number of infectious, inflammatory, 
neurodegenerative and autoimmune diseases.2 Currently, C3a is 20 
commercially produced in relatively low yields by biological 
means (recombinant expression or purification from plasma)3, 4 
resulting in a market value of approximately US$ 5000 per mg of 
protein. In addition, these approaches often require protein 
purification tags and additional steps for their removal and suffer 25 
from the inherent lability of C3a in biological fluids. C3a is 
rapidly inactivated within seconds by carboxypeptidase–mediated 
cleavage of a single C-terminal arginine residue (Arg77).5, 6 The 
resulting protein, C3a-desArg (also termed acylation-stimulating 
protein, ASP), does not bind C3aR, lacks any pro-inflammatory 30 
activity but instead has been shown to stimulate triglyceride 
synthesis and glucose uptake in adipose tissue.7-9 To circumvent 
the problems associated with the isolation of C3a from biological 
sources we sought a total chemical synthesis approach enabling 
preparation of homogenous full length C3a. 35 
Human C3a is a 77 residue protein containing three 
intramolecular disulfide bonds between C22-C49, C23-C56, and 
C36-C57.10, 11 Because polypeptides of this size are difficult to 
obtain in high purity by standard stepwise solid phase peptide 
synthesis (SPPS),12 we envisioned a fragment ligation approach 40 
by employing Kent’s native chemical ligation (NCL).13 The 77 
amino acid polypeptide chain is retro-synthetically split into three 
peptide segments of about similar length and the three 
polypeptides are then joined consecutively in the C- to N-
terminal direction by NCL as shown in Scheme 1. Temporary 45 
protection of Cys23 was realized by substitution with thiazoldine-
4-carboxylic acid (Thz).14 The individual fragments C3a[1-22]-α-
thioester, C3a[23-48]-α-thioester and C3a[49-77] were prepared 
by highly optimized in situ neutralization tert-butyloxycarbonyl 
(Boc) SPPS in high yield and purity.15 Both ligations and the 50 
intermediate conversion of Thz23 to Cys23 were carried out in 
one-pot fashion.14 The first NCL was carried out in 6M guanidine 
hydrochloride, 200 mM Na2HPO4, 50 mM Tris(2-
carboxyethyl)phosphine•HCl (TCEP) and 50 mM 4-
mercaptophenylacetic acid (MPAA), pH 7.1. The reaction was 55 
complete after 6h after which methoxyamine HCl was added and 
the pH adjusted to 4.0. After completion of the deprotection 
reaction, the mixture was readjusted to pH 7.1 and the second 
ligation initiated by adding C3a[1-22]-α-thioester (complete after 
6 h). This one-pot approach afforded fully reduced C3a[1-77] 60 
without purification of intermediate products in short time (~24 
h), good yield (41%) and high purity (SI Figure 1).  
The final folding of a cysteine-rich polypeptide chain into its 3D 
structure can often be problematic because they tend to yield 
multiple disulfide isomers that are difficult to separate and result 65 
in lower overall yield. This often necessitates optimization of 
folding conditions on a case-by-case basis. We found that folding 
and correct formation of the three disulfide bonds of C3a in 50 
mM Na2HPO4, pH 7.5 supplemented with a redox system of 8 
mM reduced glutathione, 1 mM oxidized glutathione was 70 
quantitative after 2 h at room temperature (Figure 1A) and native 
C3a was recovered in excellent yield after preparative RP-HPLC 
 
Scheme 1: Chemical synthesis of human C3a. a: native 
chemical ligation; b: Thz  Cys conversion; c: folding and 
disulfide formation. The amino acid sequence is given in the 
lower section with cysteines in bold, ligation sites underlined 
and connectivity of the three disulfides indicated. 
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purification (61%). MS analysis suggested formation of the three 
disulfide bonds [observed MW: 9088.71±0.2 Da; calculated MW: 
9088.65 Da (average isotope composition)]. Further HPLC 
analysis indicated that synthetic C3a was homogenous and devoid 
of truncated side-products, unlike commercially available 5 
material from biological sources (Figure 1A). 
To confirm that C3a was folded in the correct biologically active 
conformation, intracellular Ca2+ release and [125I]-C3a 
radioligand binding assays were performed on human monocyte-
derived macrophages (HMDM) expressing C3aR (Figure 1B). 10 
EC50s of 48 ± 10 nM (synthetic) and 43 ± 7 nM (commercial) 
determined in the Ca2+ release assay, as well as IC50s of 0.2 ± 0.1 
nM (synthetic) and 0.3 ± 0.1 nM (commercial) in the competitive 
radioligand binding assay are in excellent agreement with values 
reported previously16 and indicate that the synthetic material is 15 
essentially indistinguishable from plasma-derived C3a. 
Furthermore, studies conducted with the C3aR-selective 
antagonist SB29015717 as well as receptor desensitization 
experiments demonstrate that synthetic C3a is indeed selective 
for C3aR (SI Figure 4, 5).  20 
To confirm the covalent structure of the synthetic material, we 
determined the 3D structure of synthetic full-length C3a by X-ray 
crystallography. Rhomboid-shaped crystals were obtained by the 
hanging-drop vapour diffusion method using 49–51% (v/v) 2-
methyl-2,4-pentanediol (MPD) as the precipitant. Crystals 25 
appeared within 6 days after setting up the drops. The structure of 
C3a was determined by molecular replacement using the structure 
of C5a-desArg18 as a search model and refined to a resolution of 
2.1 Å, with a final R factor of 20.8% and an Rfree of 26.7%. 
Peptide backbone and amino acid side chains are generally well 30 
defined, except for residues 1-9, which are completely missing. 
Overall, the C3a structure is highly similar to the 3.2 Å structure 
of C3a-desArg described by Huber and Deisenhofer (Figure 
1C).11  
Conclusions 35 
In conclusion, we have demonstrated that total chemical synthesis 
is an efficient alternative for obtaining access to multi-milligram 
quantities of homogenous C3a. This approach gives complete 
control over the structure and will enable generation of unique 
chemical analogs of C3a (such as protease-resistant or 40 
fluorescently labeled variants) that will prove useful in future 
complement research. Based on our experience,19 the one-pot 
NCL approach developed by Bang and Kent14 is the most 
promising strategy for chemically accessing small and medium 
sized proteins up to 100 amino acids in length.  45 
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